Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD 0.0020
-0.0005 (-20.00%)
Jan 30, 2026, 1:01 PM AEST
Chimeric Therapeutics Revenue
In the fiscal year ending June 30, 2025, Chimeric Therapeutics had annual revenue of 12.68M AUD with 70.09% growth. Chimeric Therapeutics had revenue of 7.13M in the half year ending June 30, 2025, with 376.67% growth.
Revenue
12.68M
Revenue Growth
+70.09%
P/S Ratio
0.87
Revenue / Employee
n/a
Employees
n/a
Market Cap
11.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.68M | 5.23M | 70.09% |
| Jun 30, 2024 | 7.46M | 2.95M | 65.52% |
| Jun 30, 2023 | 4.51M | 1.89M | 72.16% |
| Jun 30, 2022 | 2.62M | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.29M |
| Tissue Repair | 2.63M |
| Neurotech International | 2.44M |
| Biotron | 1.81M |
| InhaleRx | 833.90K |
| Patrys | 828.54K |
| AdAlta | 677.01K |
| Bio-Gene Technology | 524.37K |